Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib plus pemetrexed-cisplatin versus pemetrexed-cisplatin as postoperative adjuvant therapy in EGFR-mutant stage II-IIIA NSCLC
ChiCTR2100043426Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jan 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of icotinib, pemetrexed, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: disease-free survival. Started Jan 2021; status: recruiting.
02
Drugs
icotinibpemetrexedcisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100043426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043426.